GLP‑1 weight‑loss drugs started as diabetes medicines. Now they’re quietly becoming one of the most powerful tools in obesity treatment — and they’re still evolving. The science is advancing quickly. The harder question is whether access, cost, and policy will keep up.

For generations, treating cancer has relied on a pretty brutal calculus: hit the body hard and hope the cancer dies first. Traditional chemotherapy is essentially a scorched-earth strategy. It works, but at a massive cost—wrecking the heart, gut, and nervous system along with the tumour. . For decades, researchers have chased a deceptively simple question: What if we could send the drug only where it’s actually needed? Antibody-drug conjugates, or ADCs, are the most promising

For decades, psychiatric drug development has operated with a deceptively simple story. Mental illness lives in the brain. Depression is a serotonin problem. Drug development followed that logic. That story isn’t exactly wrong. But it is increasingly incomplete. What if depression isn’t primarily a brain disorder - but a network disorder?

Most executive searches in life sciences begin with a familiar brief. Strong scientific background. Commercial acumen. Proven track record. It is a reasonable list. It is also increasingly insufficient. What if the leadership profile you are searching for is based on a role that no longer exists?